Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.

There’s a growing resistance to anything that’s injected into babies, vaccine or not.

Pfizer has announced the winners of the INDovation Program 2025, selecting 14 healthtech startups that will each receive grants of Rs 60 lakh along with 18 months of ...

Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...